Hedley Benjamin D, Vaidya Kedar S, Phadke Pushar, MacKenzie Lisa, Dales David W, Postenka Carl O, MacDonald Ian C, Chambers Ann F
London Regional Cancer Program, London Health Sciences Centre, 790 Commissioners Road East, London, ON, Canada N6A 4L6.
Clin Exp Metastasis. 2008;25(7):727-40. doi: 10.1007/s10585-008-9184-0. Epub 2008 Jun 10.
The majority of breast cancer related deaths occur as a result of metastasis. The failure of effective treatments for metastasis is the underlying cause for this. Much remains unknown about the process of metastasis and how best to prevent or treat metastatic breast cancer. Therefore, a better understanding of the metastatic process is needed in order to determine effective therapeutic interventions to either eradicate, or slow down metastatic outgrowth of breast cancer. Metastasis is an inefficient process, however the ability of only a small number of cells to complete this process may have serious, life-threatening consequences. Little is known about whether expression of the metastasis suppressor breast cancer metastasis suppressor 1 (BRMS1) can suppress metastatic outgrowth in different organs in multiple experimental models of metastasis, or what effect BRMS1 expression has on the various steps in metastatic cascade. In this study we investigated the effect of BRMS1 expression on organ-specific metastasis. In addition, the steps in metastasis that are inhibited by BRMS1-expression were determined. In vivo, BRMS1 expression reduced metastatic burden to liver, bone, brain, and lung in mice by at least 75% (P<0.05). Detailed quantitative analysis of the metastatic process in lung showed that BRMS1 expression significantly reduced the numbers of solitary single cells that survive after initial arrest within the lung microvasculature, and also inhibited the initiation of growth subsequent to arrest. In vitro, BRMS1 expression decreased cancer cell survival under stress conditions (hypoxia), increased anoikis, and decreased the ability of cancer cells to adhere. These novel findings demonstrate that BRMS1 is a potent suppressor of metastasis in multiple organs, and identify two steps in the metastatic process that are sensitive to inhibition by BRMS1.
大多数与乳腺癌相关的死亡是由转移导致的。有效治疗转移失败是其根本原因。关于转移过程以及如何最好地预防或治疗转移性乳腺癌,仍有许多未知之处。因此,需要更好地了解转移过程,以确定有效的治疗干预措施,从而根除或减缓乳腺癌的转移生长。转移是一个低效的过程,然而只有少数细胞完成这一过程的能力可能会产生严重的、危及生命的后果。关于转移抑制因子乳腺癌转移抑制因子1(BRMS1)的表达是否能在多种转移实验模型中抑制不同器官的转移生长,或者BRMS1表达对转移级联反应的各个步骤有何影响,目前知之甚少。在本研究中,我们调查了BRMS1表达对器官特异性转移的影响。此外,还确定了受BRMS1表达抑制的转移步骤。在体内,BRMS1表达使小鼠肝脏、骨骼、大脑和肺部的转移负担降低了至少75%(P<0.05)。对肺部转移过程的详细定量分析表明,BRMS1表达显著减少了在肺微血管内初始停滞后存活的孤立单细胞数量,并抑制了停滞后续的生长启动。在体外,BRMS1表达降低了应激条件(缺氧)下癌细胞的存活率,增加了失巢凋亡,并降低了癌细胞的黏附能力。这些新发现表明,BRMS1是多种器官转移的有效抑制因子,并确定了转移过程中对BRMS1抑制敏感的两个步骤。